Article Text

PDF
Letters
Intra-arterial chemotherapy with melphalan for intraocular retinoblastoma
  1. Sandra Bracco1,
  2. Sara Leonini1,
  3. Sonia De Francesco2,
  4. Samuele Cioni1,
  5. Paola Gennari1,
  6. Ignazio Maria Vallone1,
  7. Pietro Piu3,
  8. Daniela Galimberti4,
  9. Daniele Giuseppe Romano1,
  10. Mauro Caini4,
  11. Mariacarla De Luca2,
  12. Paolo Toti5,
  13. Paolo Galluzzi1,
  14. Theodora Hadjistilianou2,
  15. Alfonso Cerase1
  1. 1 Unit of Neuroimaging and Neurointervention (NINT), Azienda Ospedaliera Universitaria Senese (AOUS), University of Siena, Policlinico “Santa Maria alle Scotte”, Siena, Italy
  2. 2 Unit of Ophthalmology, University of Siena, Policlinico “Santa Maria alle Scotte”, Siena, Italy
  3. 3 Unit of Neurology, University of Siena, Policlinico “Santa Maria alle Scotte”, Siena, Italy
  4. 4 Unit of Pediatrics, University of Siena, Policlinico “Santa Maria alle Scotte”, Siena, Italy
  5. 5 Unit of Pathology, University of Siena, Policlinico “Santa Maria alle Scotte”, Siena, Italy
  1. Correspondence to Dr Sandra Bracco, Unit of Neuroimaging and Neurointervention, AOUS, Policlinico “Santa Maria alle Scotte”, Viale Mario Bracci, 16 - 53100 Siena, Italy; sandrabracco64{at}gmail.com

Statistics from Altmetric.com

Background

Recently, this journal published a paper from Marr et al 1 concerning multi-drug intra-arterial chemotherapy (IAC) for intraocular retinoblastoma. In many centres IAC has quickly garnered exciting interest, emerging as a promising, highly effective alternative for globe conserving treatment.2–4 In our institution, IAC with melphalan (IACM) has been performed since June 2008, and topotecan was added in June 2011. Fifty-nine patients have at least 1 year follow-up. Here we report our results obtained with IACM.

Methods

Forty-seven patients (table 1) for a total of 52 eyes with 22 newly diagnosed intraocular retinoblastomas (ND-RTBs) and 30 intraocular retinoblastomas after partial remission and/or relapses after other therapies (PR/R-RTBs) underwent IACM after a multidisciplinary group approval.5 The range of follow-up time is 19–61 months (median 39.6 months).

View this table:
Table 1

Demographics, previous therapies, modalities of intra-arterial chemotherapy with melphalan (IACM), associated therapies, and follow-up of 47 patients* with 52 eyes with intraocular retinoblastoma (RTB)

Results

Two …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.